Fig. 4From: High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatmentSLFN11 high expression patients had a trend of better survival than SLFN11 low expression patients both in stage II(a) and stage III(b) patientsBack to article page